Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aerosolized amikacin in intubated, mechanically ventilated patients with nosocomial pneumonia
2006-005079-17Phase 2Completed
- Sponsor
- Nektar Therapeutics
- Start
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amikacin in hospital-acquired pneumonia (HAP), sponsored by Nektar Therapeutics. Primary endpoints: Pharmacokinetics of aerosolized amikacin and Safety and tolerability of aerosolized amikacin. Started Jan 2007; status: completed.
02
Drugs
amikacin
03
Conditions
hospital-acquired pneumonia (HAP)
Beyond the preview
Go deeper on 2006-005079-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005079-17.